Displaying 101–125 of 10975 results for
PharmaManufacturing.com's career expert JoAnn Hines advises professionals work on your resume, write an article, start a blog, join an organization. Build your brand, one day at a time.
A cohesive strategy and top management commitment are critical to avoid the potential pitfalls of PAT projects, says IBS Caribe CEO Manuel Hormaza.
Attention, corporate bean counters: PAT is not a magic bullet for reducing QC headcounts. In fact, it may require hiring more people, but the efforts will pay off in improved efficiencies and lower costs.
These are exciting times, says author Michael J. Miller, as 19th-century microbiological methods make way for rapid detection, quantification and characterization technologies.
The need for increased barrier properties and a right first time approach to packaging is driving new technologies and an open, scientific approach to design and implementation.
The Agency has supply chain risk all wrong and needs to dramatically improve its IT infrastructure, say two former FDA experts.
Q: When measuring a process step, what is the difference between a "monitor" and an "analyzer?"
By adding channel-commerce management software to its mix, a leader in pharmaceutical supply chain security strengthens its data-management capabilities.
Both HF and UHF are here to stay at the item level. ABI Researchs Sara Shah explains what it means, and provides an exclusive excerpt from her most recent report on RFID in the drug industry.
Vision systems are essential for maintaining product and packaging integrity and quality, but their integration requires a healthy mix of art and science.
This year's event builds upon the success of the 2005 show, with increases in both exhibitors and educational sessions.
Will FDAs emphasis on risk management bring new clarity to an unpopular regulation?
Overall equipment effectiveness (OEE) can be useful in developing a pharmaceutical manufacturing excellence program, and provide a welcome bottom-line boost.
In this article, originally published in Biopharm International and reprinted on Southern Medical Associates' web site, Michelle Antonelli, Ph.D., discusses how outsourcing helped Serono improve a purification process.
Columnist Emil Ciurczak urges pharmaceutical manufacturers to realize that FDA personnel and instrument vendors are on their side, and that talking with them about PAT will be more fruitful than relying on word of mouth.
When is an aspirin tablet like a yacht? According to Jack Carroll, the answer to this riddle lies in five S-factors: Staff, Select, Strategize, Spend and finally, Supplant a GMP-tested product line with its parallel PAT counterpart.
"NIR person" and physical chemist Emil Ciurczak provides a thorough analysis of this year's IFPAC conference, held Feb. 21-23 in Arlington, Va.
This two-part series will examine energy use within pharmaceutical facilities, summarize best practices and examine potential savings and return on investment. In this first article, we will focus on efficient use of motors, drives and pumps, both for process equipment and compressed air systems.
FDAs recent guidance on pharmacogenomics reduces manufacturers risks in evaluating genomic data. Will it spur development of more targeted therapies?
Some pharmaceutical plants may soon wear this badge of energy efficiency honor.
RFIDs real benefits are only found in the data and come from good systems design, as prominent case studies illustrate.
Keeping up-to-date with shifting legislation is a prerequisite for e-pedigree implementation; RFID is not.
FFFs Patrick Schmidt discusses the cutting edge of electronic pedigrees, and shares IT challenges and the benefits of leading rather than lagging.
As pharmaceutical companies increasingly focus on regulatory concerns, a new executive role has emerged almost overnight. The latest star in the C-level pantheon at most drug makers is the chief compliance officer (CCO). What once was viewed as a part-time task, merely part of a chief legal ...
FDA has yet to issue guidance on biosimilars, but scientific advances promise to aid regulators and enable quality by design.